AmyriAD Therapeutics B.V. – Trademark Portfolio
Entity Type: 99
AmyriAD Therapeutics B.V. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include MEMORIES ARE WORTH FIGHTING FOR.
444 S. Flower Street, Suite 1300
Los Angeles 90071
Showing of trademarks Trademarks
Trademark Classifications
AmyriAD Therapeutics B.V.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does AmyriAD Therapeutics B.V. have?
AmyriAD Therapeutics B.V. has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.
What trademark classes does AmyriAD Therapeutics B.V. file in?
AmyriAD Therapeutics B.V. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are AmyriAD Therapeutics B.V.'s most well-known trademarks?
AmyriAD Therapeutics B.V.'s registered trademark portfolio includes well-known marks such as MEMORIES ARE WORTH FIGHTING FOR. These are among 2 currently registered trademarks in the portfolio.
What is AmyriAD Therapeutics B.V.'s trademark registration success rate?
AmyriAD Therapeutics B.V. has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.